Most cited papers in Ferrocene Chemistry and Applications
What are the most cited papers in Ferrocene Chemistry and Applications?
The most cited paper in Ferrocene Chemistry and Applications is "Platinum Compounds: a New Class of Potent Antitumour Agents" (Barnett Rosenberg, Loretta Vancamp, James Edward Trosko et al., 1969), with 3,961 citations. Next come "ACETYLATION AND METHYLATION OF HISTONES AND THEIR POSSIBLE ROLE IN THE REGULATION OF RNA SYNTHESIS" (2,629) and "6‐31G* basis set for third‐row atoms" (2,272).
Showing 50 of 100 papers. Every paper with more than 428 citations is listed.
| # | Paper | ||
|---|---|---|---|
| 1 | Platinum Compounds: a New Class of Potent Antitumour Agents Barnett Rosenberg, Loretta Vancamp, James Edward Trosko et al. · Nature | Apr 1969 | 3,961 |
| 2 | ACETYLATION AND METHYLATION OF HISTONES AND THEIR POSSIBLE ROLE IN THE REGULATION OF RNA SYNTHESIS V. G. Allfrey, Robert D. Faulkner, A. E. Mirsky · Proceedings of the National Academy of Sciences | May 1964 | 2,629 |
| 3 | 6‐31G* basis set for third‐row atoms Vitaly A. Rassolov, Mark A. Ratner, John Anthony Pople et al. · Journal of Computational Chemistry | 23 Apr 2001 | 2,272 |
| 4 | Cisplatin as an Anti-Tumor Drug: Cellular Mechanisms of Activity, Drug Resistance and Induced Side Effects Ana-Maria Florea, Dietrich Büsselberg · Cancers | 15 Mar 2011 | 1,785 |
| 5 | Cisplatin: The first metal based anticancer drug Sumit Ghosh · Bioorganic Chemistry | 11 Apr 2019 | 1,768 |
| 6 | Organometallic Anticancer Compounds Gilles Gasser, Ingo Ott, Nils Metzler‐Nolte · Journal of Medicinal Chemistry | 15 Nov 2010 | 1,619 |
| 7 | Bioorganometallic Chemistry of Ferrocene Dave R. van Staveren, Nils Metzler‐Nolte · Chemical Reviews | Dec 2004 | 1,315 |
| 8 | New trends for metal complexes with anticancer activity Pieter C. A. Bruijnincx, Peter John Sadler · Current Opinion in Chemical Biology | 22 Feb 2008 | 1,307 |
| 9 | Tris(phenanthroline)ruthenium(II) enantiomer interactions with DNA: Mode and specificity of binding Sirasani Satyanarayana, James C. Dabrowiak, Jonathan Brad Chaires · Biochemistry | 16 Mar 1993 | 1,197 |
| 10 | The development of anticancer ruthenium( ii ) complexes: from single molecule compounds to nanomaterials Leli Zeng, Pranav Gupta, Yanglu Chen et al. · Chemical Society Reviews | 2017 | 1,019 |
| 11 | Factor Stimulating Transcription by RNA Polymerase Richard R. Burgess, ANDREW A. TRAVERS, John J. Dunn et al. · Nature | 1969 | 1,006 |
| 12 | Bioorganometallic chemistry—from teaching paradigms to medicinal applications Christian G. Hartinger, Paul J. Dyson · Chemical Society Reviews | 25 Nov 2008 | 985 |
| 13 | Metal complexes in cancer therapy – an update from drug design perspective Umar Ndagi, Ndumiso Nhlakanipho Mhlongo, Mahmoud E. S. Soliman · Drug Design Development and Therapy | Mar 2017 | 932 |
| 14 | Discovery of dendrimers and dendritic polymers: A brief historical perspective* Donald A. Tomalia, Jean M. J. Fréchet · Journal of Polymer Science Part A Polymer Chemistry | 21 Jun 2002 | 910 |
| 15 | Suprasupermolecules with Novel Properties: Metallodendrimers George R. Newkome, Enfei He, Charles N. Moorefield · Chemical Reviews | 12 Jun 1999 | 898 |
| 16 | A study of the interactions of some polypyridylruthenium(II) complexes with DNA using fluorescence spectroscopy, topoisomerisation and thermal denaturation John M. Kelly, Alessandro Tossi, David J. McConnell et al. · Nucleic Acids Research | 1985 | 885 |
| 17 | Antitumour metal compounds: more than theme and variations Michael A. Jakupec, Mathea Sophia Galanski, Vladimir B. Arion et al. · Dalton Transactions | 7 Nov 2007 | 849 |
| 18 | Metallo-intercalators and metallo-insertors Brian M. Zeglis, Valérie C. Pierre, Jacqueline K. Barton · Chemical Communications | 2007 | 847 |
| 19 | On the medicinal chemistry of gold complexes as anticancer drugs Ingo Ott · Coordination Chemistry Reviews | 28 Feb 2009 | 826 |
| 20 | In Vitro and in Vivo Evaluation of Ruthenium(II)−Arene PTA Complexes C. Scolaro, Alberta Bergamo, Laura Brescacin et al. · Journal of Medicinal Chemistry | 21 May 2005 | 782 |
| 21 | Metal-based antitumour drugs in the post genomic era Paul J. Dyson, Gianni Sava · Dalton Transactions | 2006 | 770 |
| 22 | Organometallic chemistry, biology and medicine: ruthenium arene anticancer complexes Yaw Kai Yan, Michael Melchart, Abraha Habtemariam et al. · Chemical Communications | 2005 | 759 |
| 23 | Metals and DNA: Molecular Left-Handed Complements Jacqueline K. Barton · Science | 15 Aug 1986 | 753 |
| 24 | Ruthenium(ii) polypyridyl complexes and DNA—from structural probes to cellular imaging and therapeutics Martin R. Gill, Jim A. Thomas · Chemical Society Reviews | 2012 | 749 |
| 25 | Alkyl and aryl derivatives of π-cyclopentadienyl compounds of chromium, molybdenum, tungsten, and iron T. S. Piper, Grant R. Wilkinson · Journal of Inorganic and Nuclear Chemistry | Sep 1956 | 745 |
| 26 | Metal Complexes as DNA Intercalators Hong‐Ke Liu, Peter John Sadler · Accounts of Chemical Research | 29 Mar 2011 | 745 |
| 27 | Une nouvelle famille de molecules : les metallo-catenanes Christiane O. Dietrich-Buchecker, Jean‐Pierre Sauvage, Jean‐Pierre Kintzinger · Tetrahedron Letters | 1983 | 740 |
| 28 | Hyperbranched polymers 10 years after Young Ho Kim · Journal of Polymer Science Part A Polymer Chemistry | Aug 1998 | 735 |
| 29 | Update of the Preclinical Situation of Anticancer Platinum Complexes: Novel Design Strategies and Innovative Analytical Approaches Mathea Sophia Galanski, Michael A. Jakupec, Bernhard K. Keppler · Current Medicinal Chemistry | Aug 2005 | 731 |
| 30 | Chemistry of dibenzylideneacetone-palladium(0) complexes Toshina Ukai, Hiroshi Kawazura, Yoshio Ishii et al. · Journal of Organometallic Chemistry | 1974 | 727 |
| 31 | Kinetically inert transition metal complexes that reversibly bind to DNA Clive L. Metcalfe, Jim A. Thomas · Chemical Society Reviews | 2003 | 725 |
| 32 | Chelation or Non‐Chelation Control in Addition Reactions of Chiral α‐ and β‐ Alkoxy Carbonyl Compounds [New Synthetic Methods (44)] Manfred T. Reetz · Angewandte Chemie International Edition in English | Aug 1984 | 687 |
| 33 | Ruthenium metallopharmaceuticals Michael John Clarke · Coordination Chemistry Reviews | 2003 | 684 |
| 34 | Why is Ferrocene so Exceptional? Didier Astruc · European Journal of Inorganic Chemistry | 5 Oct 2016 | 662 |
| 35 | Biochemical Mechanisms of Cisplatin Cytotoxicity Victoria Cepeda, Miguel Angel Fuertes, Josefina Castilla et al. · Anti-Cancer Agents in Medicinal Chemistry | 2007 | 648 |
| 36 | Areneruthenium complexes as anticancer agents Georg Süß‐Fink · Dalton Transactions | 23 Oct 2009 | 638 |
| 37 | Toward Multi-Targeted Platinum and Ruthenium Drugs—A New Paradigm in Cancer Drug Treatment Regimens? Reece G. Kenny, Celine J. Marmion · Chemical Reviews | 14 Jan 2019 | 633 |
| 38 | Classical and Non‐Classical Ruthenium‐Based Anticancer Drugs: Towards Targeted Chemotherapy Wee Han Ang, Paul J. Dyson · European Journal of Inorganic Chemistry | 21 Sep 2006 | 626 |
| 39 | Quest for Novel Chemical Entities through Incorporation of Silicon in Drug Scaffolds Remya Ramesh, D. Srinivasa Reddy · Journal of Medicinal Chemistry | 17 Oct 2017 | 623 |
| 40 | Square-Planar Pd(II), Pt(II), and Au(III) Terpyridine Complexes: Their Syntheses, Physical Properties, Supramolecular Constructs, and Biomedical Activities Ibrahim Eryazici, Charles N. Moorefield, George R. Newkome · Chemical Reviews | Jun 2008 | 621 |
| 41 | New clues for platinum antitumor chemistry: Kinetically controlled metal binding to DNA Jan Reedijk · Proceedings of the National Academy of Sciences | 24 Mar 2003 | 616 |
| 42 | The medicinal chemistry of ferrocene and its derivatives Malay Patra, Gilles Gasser · Nature Reviews Chemistry | 6 Sep 2017 | 612 |
| 43 | Non Platinum Metal Complexes as Anti‐cancer Drugs Ingo Ott, Ronald Gust · Archiv der Pharmazie | 22 Feb 2007 | 611 |
| 44 | Synthesis and Antimalarial Activity in Vitro and in Vivo of a New Ferrocene−Chloroquine Analogue Christophe Biot, Guillaume Glorian, Lucien A. Maciejewski et al. · Journal of Medicinal Chemistry | Nov 1997 | 602 |
| 45 | Current applications and future potential for bioinorganic chemistry in the development of anticancer drugs Sabine van Rijt, Peter John Sadler · Drug Discovery Today | 25 Sep 2009 | 594 |
| 46 | Nickel-Phosphine Complex-Catalyzed Grignard Coupling. I. Cross-Coupling of Alkyl, Aryl, and Alkenyl Grignard Reagents with Aryl and Alkenyl Halides: General Scope and Limitations Kohei Tamao, Koji Sumitani, Yoshihisa Kiso et al. · Bulletin of the Chemical Society of Japan | Jul 1976 | 590 |
| 47 | Recent developments in ruthenium anticancer drugs Aviva Levina, Anannya Mitra, Peter A. Lay · Metallomics | 2009 | 588 |
| 48 | Asymmetric Catalysis with Chiral Ferrocene Ligands Li‐Xin Dai, Tao Tu, Shu‐Li You et al. · Accounts of Chemical Research | 29 May 2003 | 581 |
| 49 | Ferrocifen type anti cancer drugs Gérard Jaouen, Anne Vessières, Siden Top · Chemical Society Reviews | 2015 | 579 |
| 50 | Organoiridium Complexes: Anticancer Agents and Catalysts Zhe Liu, Peter John Sadler · Accounts of Chemical Research | 20 Feb 2014 | 574 |
Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for a field when OpenAlex files it under one of the field's topics; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.